1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier
Material Name: Celontin (Methsuximide) Capsules 150 and 300 mg
Trade Name: Celontin®, Petinutin
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as anticonvulsant

Details of the Supplier of the Safety Data Sheet
Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture
GHS - Classification
Acute Oral Toxicity: Category 4
Reproductive Toxicity: Category 2

EU Classification:
EU Indication of danger: Harmful
Toxic to Reproduction: Category 3

EU Risk Phrases:
R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.

Label Elements
Signal Word: Warning
Hazard Statements:
H302 - Harmful if swallowed
H361d - Suspected of damaging the unborn child
Precautionary Statements:

P202 - Do not handle until all safety precautions have been read and understood
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P281 - Use personal protective equipment as required
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
P330 - Rinse mouth
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards

Australian Hazard Classification (NOHSC):


Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Methsuximide</td>
<td>77-41-8</td>
<td>201-026-7</td>
<td>Xn;R22</td>
<td>Acute Tox.4 (H302)</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat.3;R63</td>
<td>Repr.2 (H361d)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>D &amp; C yellow No. 10</td>
<td>8004-92-0</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>FD&amp;C yellow No.6 aluminum lake</td>
<td>15790-07-5</td>
<td>239-888-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Gelatin</td>
<td>9000-70-8</td>
<td>232-554-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
7. HANDLING AND STORAGE

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

<table>
<thead>
<tr>
<th>Storage Conditions:</th>
<th>Specific end use(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Store as directed by product packaging.</td>
<td>Pharmaceutical drug product</td>
</tr>
</tbody>
</table>

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

<table>
<thead>
<tr>
<th>Sodium lauryl sulfate</th>
<th>Pfizer OEL TWA-8 Hr: 0.3 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colloidal silicon dioxide</td>
<td>Australia TWA 2 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Austria OEL - MAKs 4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>0.3 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Czech Republic OEL - TWA 0.1 mg/m³</td>
</tr>
<tr>
<td></td>
<td>4.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Estonia OEL - TWA 2 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Finland OEL - TWA 5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Germany - TRGS 900 - TWAs 4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Germany (DFG) - MAK 4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Ireland OEL - TWAs 6 mg/m³</td>
</tr>
<tr>
<td></td>
<td>2.4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Latvia OEL - TWA 1 mg/m³</td>
</tr>
<tr>
<td></td>
<td>OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf Listed</td>
</tr>
<tr>
<td></td>
<td>Slovakia OEL - TWA 4.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Switzerland OEL -TWAs 4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>0.3 mg/m³</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Starch</th>
<th>ACGIH Threshold Limit Value (TWA) 10 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Australia TWA 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Belgium OEL - TWA 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Bulgaria OEL - TWA 10.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Czech Republic OEL - TWA 4.0 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Greece OEL - TWA 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Ireland OEL - TWAs 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>OSHA - Final PELS - TWAs: 15 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Portugal OEL - TWA 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Slovakia OEL - TWA 4 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Spain OEL - TWA 10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Switzerland OEL -TWAs 3 mg/m³</td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Methsuximide

Pfizer OEL TWA-8 Hr: 0.7 mg/m³

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule
Odor: Odorless
Molecular Formula: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)
Gelatin
No data available
D & C yellow No. 10
No data available
Colloidal silicon dioxide
No data available
Sodium lauryl sulfate
No data available
FD&C yellow No.6 aluminum lake
No data available
Starch
No data available
Methsuximide
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
SAFETY DATA SHEET

Flammability:
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur.

10. STABILITY AND REACTIVITY

- Reactivity: No data available
- Chemical Stability: Stable under normal conditions of use.
- Possibility of Hazardous Reactions
  - Oxidizing Properties: No data available
  - Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  - Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  - Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
- General Information: There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients.
- Short Term: Antiepileptic drug: may cause nervous system effects
- Long Term: Animal studies have shown a potential to cause adverse effects on the fetus.
- Known Clinical Effects: The most common adverse effects seen with the therapeutic use of this drug are nausea or vomiting, constipation, weight loss, and epigastric or abdominal pain. Other less common effects include CNS depression (headache, drowsiness, dizziness, incoordination, and blurred vision), behavioral changes, hematological effects (eosinophilia, leukopenia, monocytosis, and pancytopenia with or without bone-marrow depression), and skin reactions (urticaria and Stevens-Johnson syndrome) have also been reported. Psychosis, suicidal behavior, and auditory hallucinations have been reported rarely.

Acute Toxicity: (Species, Route, End Point, Dose)
- D & C yellow No. 10
  - Rat Oral LD50 2000 mg/kg
- Sodium lauryl sulfate
  - Rat Oral LD50 1288 mg/kg
- Methsuximide
  - Mouse Oral LD50 900-1405 mg/kg
  - Rat Oral LD50 960 mg/kg
- Inhalation Acute Toxicity No data available
- Ingestion Acute Toxicity See Acute toxicity table.

Irritation / Sensitization: (Study Type, Species, Severity)
- Sodium lauryl sulfate
  - Eye Irritation Rabbit Moderate
  - Skin Irritation Rabbit Mild Moderate
11. TOXICOLOGICAL INFORMATION

Skin Sensitization - GPMT  Guinea Pig  Negative
Skin Sensitization - LLNA  Mouse  Negative
No data available

Skin Irritation / Sensitization
No data available

Chronic Toxicity:
One-year oral toxicity studies were conducted in dogs and monkeys. No signs of toxicity were seen in dogs at doses up to 80 mg/kg/day. Monkeys exhibited dose-dependent, slight to marked motor incoordination.

Chronic Effects/Carcinogenicity
No data available

Subchronic Effects
The only effects seen in rodents during 28-day (mice) and 26-week (rats) studies were slight decreases in weight gain.

Teratogenicity
Methsuximide was reported to be teratogenic in mice, causing primarily skeletal and cardiovascular defects with an incidence of 51%.

Sodium lauryl sulfate
Bacterial Mutagenicity (Ames)  Salmonella  Negative

Mutagenicity
No data available

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Colloidal silicon dioxide
IARC:
Group 3 (Not Classifiable)

Additional Information:
There have been a few cases of women treated with methsuximide during pregnancy and no adverse effects were seen in the treated women. However, in general there are reports that suggest an association between the use of anticonvulsant drugs by women with epilepsy and increased incidence of birth defects in their offspring. The data are inadequate to establish a definitive cause and effect relationship. In addition, genetic factors or the epileptic condition itself may play a greater role in causation of birth defects than the drug therapy.

12. ECOLOGICAL INFORMATION

Environmental Overview:
The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate
Oncorhynchus mykiss (Rainbow Trout)  LC50  96 Hours  3.6 mg/L

Persistence and Degradability:
No data available

Bio-accumulative Potential:
No data available

Mobility in Soil:
No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

D & C yellow No. 10

CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
EU EINECS/ELINCS List Not Listed

Sodium lauryl sulfate

CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 6
EU EINECS/ELINCS List 205-788-1
15. REGULATORY INFORMATION

FD&C yellow No.6 aluminum lake
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
  - Australia (AICS): Present
- EU EINECS/ELINCS List: 239-888-1

Colloidal silicon dioxide
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
  - Australia (AICS): Present
- EU EINECS/ELINCS List: 231-545-4

Starch
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
  - Australia (AICS): Present
  - REACH - Annex IV - Exemptions from the obligations of Register:
  - EU EINECS/ELINCS List: 232-679-6

Gelatin
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
  - Australia (AICS): Present
- EU EINECS/ELINCS List: 232-554-6

Methsuximide
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Australia (AICS): Present
  - Standard for the Uniform Scheduling for Drugs and Poisons:
  - EU EINECS/ELINCS List: 201-026-7

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.2; H361d - Suspected of damaging the unborn child

Toxic to Reproduction: Category 3
Xn - Harmful

R22 - Harmful if swallowed.
R63 - Possible risk of harm to the unborn child.
SAFETY DATA SHEET

Material Name: Celontin (Methsuximide) Capsules 150 and 300 mg
Revision date: 10-Mar-2015

Data Sources: Safety data sheets for individual ingredients. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 10-Mar-2015
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet